myricetin 3-O-β-D-xylopyranoside | 102849-44-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: myricetin 3-O-β-D-xylopyranoside
• 英文别名: myricetin-3-O-beta-D-xylopyranoside；5,7-dihydroxy-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
• CAS: 102849-44-5
• 化学式: C₂₀H₁₈O₁₂
• 分子量: 450.356
• InChiKey: SBEOEJNITMVWLK-CFSKSFDZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  207
• 氢给体数：
  8
• 氢受体数：
  12

文献信息

• [EN] DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES<br/>[FR] DÉRIVÉS DE DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL
  申请人：PFIZER

  公开号：WO2010023594A1

  公开（公告）日：2010-03-04

  Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).The compounds disclosed herein are useful for the prevention and treatment of obesity and its associated co-morbidities, inn particular type Il (type 2) diabetes.

  本文描述了化合物(I)的结构式及其用途，用于治疗由钠葡萄糖转运体抑制剂（特别是SGLT2抑制剂）介导的疾病、状况和/或紊乱。本文披露的化合物对于预防和治疗肥胖及其相关的共病症特别是II型（2型）糖尿病具有用处。
• DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES
  申请人：Mascitti Vincent

  公开号：US20100056618A1

  公开（公告）日：2010-03-04

  Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

  本文介绍了化学式(I)的化合物以及它们用于治疗由钠-葡萄糖转运抑制剂（特别是SGLT2抑制剂）介导的疾病、病状和/或疾患的用途。
• SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10285973B2

  公开（公告）日：2019-05-14

  The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.

  本发明涉及某些SGLT-2抑制剂，如ertugliflozin或其共晶体或药学上可接受的盐，用于治疗和/或预防肾功能损害或慢性肾病（CKD）患者的代谢紊乱，如1型或2型糖尿病或糖尿病前期。本发明还涉及预防动物缺血性中风和近头脑外伤发生后神经元损伤的方法，包括向需要此类治疗的动物施用治疗有效量的ertugliflozin或其共晶体或药学上可接受的盐的步骤。
• Anti-inflammatory cranberry flavonol extract preparations
  申请人：Vorsa Nicholi

  公开号：US20060088610A1

  公开（公告）日：2006-04-27

  The present invention is directed to extracts of cranberries ( Vaccinium macrocarpon ) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-α-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

  本发明涉及蔓越莓（Vaccinium macrocarpon）的提取物。 蔓越莓 )的提取物，该提取物包含基本不含花青素和原花青素的混合黄酮醇或纯化的蔓越莓黄酮醇化合物，包括杨梅素-3-β-木吡喃糖苷槲皮素-3-β-葡萄糖苷、槲皮素-3-α-阿拉伯吡喃糖苷、3′-甲氧基槲皮素-3-α-木吡喃糖苷、槲皮素-3-O-(6″-对香豆酰基)-β-半乳糖苷和槲皮素-3-O-(6″-苯甲酰基)-β-半乳糖苷。本发明还包括使用这些提取物以及包含蔓越莓黄酮醇化合物槲皮素-3-α-阿拉伯呋喃糖苷的提取物来治疗炎症性疾病。此外，还叙述了利用本发明提取物或化合物的药物、食品、膳食补充剂和化妆品组合物。
• BEVERAGE COMPOSITION
  申请人：Eckes-Granini Group GmbH

  公开号：EP2299852B1

  公开（公告）日：2015-08-05